Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor.

Area of Science:

• Oncology
• Molecular Diagnostics
• Cancer Therapeutics

Background:

• Human Epidermal Growth Factor Receptor 2 (HER2) is a critical biomarker and therapeutic target in various cancers, including breast and gastric tumors.
• Recent approvals of HER2-targeted therapies for pan-tumor indications underscore the expanding clinical relevance of HER2 alterations.
• Current lack of standardized HER2 testing guidelines in a pan-tumor context leads to clinical practice variability and suboptimal therapy implementation.

Purpose of the Study:

• To address the need for standardized HER2 testing across diverse malignancies.
• To provide comprehensive recommendations for diagnostic strategies and testing methodologies for HER2 overexpression.
• To optimize the clinical application of HER2-targeted therapies beyond traditional indications.

Main Methods:

• Development of a consensus by a multidisciplinary panel of Chinese experts.
• Review of current diagnostic strategies and testing methodologies for HER2 overexpression.
• Formulation of recommendations for clinical application of HER2 detection.

Main Results:

• Establishment of a unified framework for assessing HER2 overexpression.
• Recommendations cover diagnostic strategies, testing methodologies, and clinical applications.
• The consensus provides guidance for consistent and precise HER2 testing.

Conclusions:

• The developed consensus aims to enhance the precision of HER2 testing.
• Optimizing patient selection for HER2-targeted therapies is a key outcome.
• Improved clinical outcomes are anticipated across a spectrum of HER2 overexpression malignancies.